Abstract:Objective To investigate the changes in the serum level of high-sensitivity C-reactive protein (hs-CRP) and coagulation function in patients with chronic nephritis and spleen and kidney deficiency syndrome, as well as the therapeutic effect of Shenkang Granule. Methods A total of 55 patients with chronic nephritis and spleen and kidney deficiency syndrome were enrolled and randomly divided into control group with 28 patients and experimental group with 27 patients, and another 20 healthy persons were enrolled as normal control group. The patients in both groups were given conventional basic treatment, and those in the experimental group were given Shenkang Granule in addition. The course of treatment was 8 weeks. The clinical outcome was compared between the two groups, and the changes in urinary albumin-to-creatinine ratio (UACR), 24-hour urinary protein (24hUP), serum albumin (Alb), blood urea nitrogen, serum creatinine, hs-CRP, prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), and fibrinogen (Fib) after treatment were measured for both groups. Results The experimental group had significantly better clinical outcomes than the control group (P<0.05). After treatment, the experimental group and the control group had significant reductions in 24hUP and UACR and a significant increase in serum Alb level (P<0.05), and the experimental group had significantly better improvements than the control group (P<0.05). Compared with the normal control group, the experimental group and the control group had significantly higher serum levels of hs-CRP and Fib and significantly shorter PT, APTT, and TT before treatment (P<0.05). After treatment, the experimental group and the control group had significant reductions in the serum levels of hs-CRP and Fib and significant increases in PT, APTT, and TT (P<0.05), and the experimental group had significantly better improvements than the control group (P<0.05). Conclusion In patients with chronic nephritis and spleen and kidney deficiency syndrome, Shenkang Granule can effectively improve their clinical symptoms and reduce urinary protein, possibly by reducing serum hs-CRP level, inhibiting in vivo inflammatory response, and improving hypercoagulability.